Figure 3
From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Activity of the central cell signaling pathways in response to dual PI3K and MEK inhibition in dual inhibition-sensitive cancer cell lines. (A) Western blot analysis for pAKT, pERK1/2, pS6 and p4E-BP1 and their corresponding total proteins in response to treatment with the PI3K inhibitors ZSTK474 and PI-103 and the MEK inhibitor CI-1040 singly or in combination for 6h. (B) Western blot analysis of the same proteins as in panel A when the inhibitor combinations were administered alternately for the times indicated (15 min or 6 h). The cells were exposed to dual inhibition for 15 min, the inhibitors were washed out and treatment was continued with a single inhibitor for an additional 6 h.